Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment.
Chromogranin A, chromogranin B and secretogranin II belong to the chromogranin family which consists of large protein molecules that are found in large dense core vesicles. Chromogranins are endoproteolytically processed to smaller peptides. This study was designed to elucidate the regulation of chromgranin expression by acute and subchronic phencyclidine administration. The behavioral syndrome produced by phencyclidine represents a pharmacological model for some aspects of schizophrenia [Jentsch and Roth (1999) Neuropsychopharmacology 20, 201-225]. Tissue concentrations of chromogranins were measured with specific radioimmunoassays. Alterations in secretogranin II gene expression were investigated by in situ hybridization. A single dose of phencyclidine (10mg/kg) led to a transient decrease in secretoneurin tissue levels in the prefrontal cortex after 4h followed by an increase in secretoneurin tissue levels after 12h. Repeated phencyclidine treatment (10mg/kg/day) for five days resulted in elevated secretoneurin levels in cortical areas whereas chromogranin A and chromogranin B tissue levels were unchanged. After the same treatment, a significant increase in the number of secretoneurin containing neurons was found in cortical layers II-III, and V-VI as revealed by immunocytochemistry. The increases in secretoneurin levels were paralleled by an increased number of secretogranin II messenger RNA containing neurons as well as by an increased expression of secretogranin II by individual neurons. The present study shows that secretoneurin II tissue concentration and secretogranin II messenger RNA expression is distinctly altered after acute and subchronic phencyclidine application. From these results we suggest that phencyclidine may induce synaptic alterations in specific brain areas and may contribute to a better understanding of synaptic dysfunction which may also occur in schizophrenia.
Marksteiner
J
J
Department of Psychiatry, University of Innsbruck, A-6020, Innsbruck, Austria. j.marksteiner@uibk.ac.at
Weiss
U
U
Weis
C
C
Laslop
A
A
Fischer-Colbrie
R
R
Humpel
C
C
Feldon
J
J
Fleischhacker
W W
WW
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D053379:Chromogranin A; D053378:Chromogranin B; D002864:Chromogranins / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D007150:Immunohistochemistry; D008297:Male; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D009479:Neuropeptides / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D010446:Peptide Fragments / Q000276:immunology / Q000493:pharmacokinetics; D010622:Phencyclidine / Q000494:pharmacology*; D011506:Proteins / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D011605:Psychoses, Substance-Induced / Q000378:metabolism* / Q000503:physiopathology; D012333:RNA, Messenger / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D012559:Schizophrenia / Q000378:metabolism / Q000503:physiopathology; D053381:Secretogranin II; D022142:Secretory Vesicles / Q000187:drug effects / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D053379:Chromogranin A; D053378:Chromogranin B; D002864:Chromogranins; D018691:Excitatory Amino Acid Antagonists; D009479:Neuropeptides; D010446:Peptide Fragments; D011506:Proteins; D012333:RNA, Messenger; D053381:Secretogranin II; C506153:chromogranin A, rat; C506140:chromogranin B, rat; C081159:secretoneurin; D010622:Phencyclidine